JP2018500878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500878A5 JP2018500878A5 JP2017523804A JP2017523804A JP2018500878A5 JP 2018500878 A5 JP2018500878 A5 JP 2018500878A5 JP 2017523804 A JP2017523804 A JP 2017523804A JP 2017523804 A JP2017523804 A JP 2017523804A JP 2018500878 A5 JP2018500878 A5 JP 2018500878A5
- Authority
- JP
- Japan
- Prior art keywords
- glycoprotein
- dengue virus
- antibody
- seq
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003886 Glycoproteins Human genes 0.000 claims 39
- 108090000288 Glycoproteins Proteins 0.000 claims 39
- 241000725619 Dengue virus Species 0.000 claims 31
- 230000003472 neutralizing effect Effects 0.000 claims 28
- 239000002245 particle Substances 0.000 claims 13
- 241000710831 Flavivirus Species 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000012472 biological sample Substances 0.000 claims 9
- 230000002163 immunogen Effects 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 206010012310 Dengue fever Diseases 0.000 claims 3
- 208000025729 dengue disease Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000006386 neutralization reaction Methods 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462074053P | 2014-11-02 | 2014-11-02 | |
| US62/074,053 | 2014-11-02 | ||
| PCT/US2015/058610 WO2016070178A1 (en) | 2014-11-02 | 2015-11-02 | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500878A JP2018500878A (ja) | 2018-01-18 |
| JP2018500878A5 true JP2018500878A5 (enExample) | 2018-12-13 |
| JP6671364B2 JP6671364B2 (ja) | 2020-03-25 |
Family
ID=55858450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523804A Expired - Fee Related JP6671364B2 (ja) | 2014-11-02 | 2015-11-02 | ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10398768B2 (enExample) |
| EP (1) | EP3212672A4 (enExample) |
| JP (1) | JP6671364B2 (enExample) |
| KR (1) | KR20170075775A (enExample) |
| CN (1) | CN107207619A (enExample) |
| AU (1) | AU2015338859A1 (enExample) |
| BR (1) | BR112017008952A2 (enExample) |
| CA (1) | CA2966198A1 (enExample) |
| MX (1) | MX2017005524A (enExample) |
| MY (1) | MY179251A (enExample) |
| SG (1) | SG11201703366RA (enExample) |
| WO (1) | WO2016070178A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10955414B2 (en) | 2016-08-01 | 2021-03-23 | Inbios International, Inc. | Immunoassay methods and compositions for detecting infection involving use of test antigens as cross-reactive control antigens |
| CN106632620B (zh) * | 2016-11-29 | 2019-08-23 | 菲鹏生物股份有限公司 | 登革病毒重组抗原及其制备方法和应用 |
| EP3606552A4 (en) | 2017-04-07 | 2020-08-05 | The Rockefeller University | COMPOSITIONS AND METHODS RELATING TO HUMAN NEUTRALIZING ANTIBODIES DIRECTED AGAINST ZIKA VIRUS AND DENGUE VIRUS 1 |
| CN110568190A (zh) * | 2019-08-30 | 2019-12-13 | 深圳国际旅行卫生保健中心 | 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法 |
| WO2021102363A1 (en) * | 2019-11-20 | 2021-05-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development |
| WO2023178310A1 (en) * | 2022-03-17 | 2023-09-21 | The University Of North Carolina At Chapel Hill | Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same |
| CN116716322B (zh) * | 2023-05-12 | 2024-05-31 | 中山大学 | 一种denv-3全长感染性克隆及其构建方法与应用 |
| WO2024238948A2 (en) * | 2023-05-17 | 2024-11-21 | University Of Iowa Research Foundation | Dengue virus serotype-specific modulation of t cell responses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| WO2003102166A2 (en) * | 2002-02-26 | 2003-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
| WO2006085983A2 (en) | 2004-07-09 | 2006-08-17 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| EP2589602B1 (en) * | 2006-08-15 | 2016-04-06 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Development of dengue virus vaccine components |
| WO2013151764A1 (en) | 2012-04-02 | 2013-10-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus epitopes |
| KR20160027019A (ko) * | 2013-06-26 | 2016-03-09 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 뎅기 바이러스 백신에 대한 방법 및 조성물 |
-
2015
- 2015-11-02 US US15/523,899 patent/US10398768B2/en not_active Expired - Fee Related
- 2015-11-02 EP EP15854399.1A patent/EP3212672A4/en not_active Withdrawn
- 2015-11-02 KR KR1020177014337A patent/KR20170075775A/ko not_active Withdrawn
- 2015-11-02 MY MYPI2017701472A patent/MY179251A/en unknown
- 2015-11-02 WO PCT/US2015/058610 patent/WO2016070178A1/en not_active Ceased
- 2015-11-02 BR BR112017008952A patent/BR112017008952A2/pt not_active Application Discontinuation
- 2015-11-02 MX MX2017005524A patent/MX2017005524A/es unknown
- 2015-11-02 CN CN201580072021.7A patent/CN107207619A/zh active Pending
- 2015-11-02 AU AU2015338859A patent/AU2015338859A1/en not_active Abandoned
- 2015-11-02 SG SG11201703366RA patent/SG11201703366RA/en unknown
- 2015-11-02 CA CA2966198A patent/CA2966198A1/en not_active Abandoned
- 2015-11-02 JP JP2017523804A patent/JP6671364B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-29 US US16/555,912 patent/US20200230224A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500878A5 (enExample) | ||
| Fougeroux et al. | Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity | |
| Sun et al. | The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice | |
| CY1124202T1 (el) | Εμβολια ανασυνδυασμενου zika | |
| Tamminen et al. | A comparison of immunogenicity of norovirus GII‐4 virus‐like particles and P‐particles | |
| JP2015524422A5 (enExample) | ||
| Lee et al. | A novel vaccination strategy mediating the induction of lung-resident memory CD8 T cells confers heterosubtypic immunity against future pandemic influenza virus | |
| PH12018500199A1 (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
| Carignan et al. | Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine | |
| RU2015155821A (ru) | Вакцины против малярии | |
| NO20090178L (no) | Vaksiner for malaria | |
| BR112014030797A2 (pt) | epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo | |
| RU2019107976A (ru) | Композиция вакцины | |
| Kim et al. | Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity | |
| Song et al. | Plant‐based, adjuvant‐free, potent multivalent vaccines for avian influenza virus via Lactococcus surface display | |
| JP2016504993A5 (enExample) | ||
| De Jong et al. | Development of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains | |
| JP2017526689A5 (enExample) | ||
| Davenport et al. | Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease | |
| RU2021109510A (ru) | Вакцинация с использованием альфа 3 домена mica/b для лечения рака | |
| RU2016133598A (ru) | Композиция микобактериального антигена | |
| Zhou et al. | An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection | |
| JP2016528176A5 (enExample) | ||
| EP4285914A3 (en) | Oncolytic virotherapy and immunotherapy | |
| Schmidt et al. | Generation of therapeutic antisera for emerging viral infections |